• Peter M Grace, Daniel Hurley, Daniel T Barratt, Anna Tsykin, Linda R Watkins, Paul E Rolan, and Mark R Hutchinson.
• Discipline of Pharmacology, School of Medical Sciences, University of Adelaide, Adelaide, Australia. peter.grace@colorado.edu
• J. Neurochem. 2012 Sep 1; 122 (5): 976-94.

AbstractA quantitative, peripherally accessible biomarker for neuropathic pain has great potential to improve clinical outcomes. Based on the premise that peripheral and central immunity contribute to neuropathic pain mechanisms, we hypothesized that biomarkers could be identified from the whole blood of adult male rats, by integrating graded chronic constriction injury (CCI), ipsilateral lumbar dorsal quadrant (iLDQ) and whole blood transcriptomes, and pathway analysis with pain behavior. Correlational bioinformatics identified a range of putative biomarker genes for allodynia intensity, many encoding for proteins with a recognized role in immune/nociceptive mechanisms. A selection of these genes was validated in a separate replication study. Pathway analysis of the iLDQ transcriptome identified Fcγ and Fcε signaling pathways, among others. This study is the first to employ the whole blood transcriptome to identify pain biomarker panels. The novel correlational bioinformatics, developed here, selected such putative biomarkers based on a correlation with pain behavior and formation of signaling pathways with iLDQ genes. Future studies may demonstrate the predictive ability of these biomarker genes across other models and additional variables.© 2012 The Authors. Journal of Neurochemistry © 2012 International Society for Neurochemistry.

45 keywords...

hide…